EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Anti-TROP2 Antibody Drug Conjugates in EGFR-Mutant Non-Small Cell Lung Cancer: Biological Rationale and Clinical Challenges

Laura Bonanno, Alberto Ronchi, Loc Carlo Bao, Francesca Pante, Sara Sangiorgi, Giulia Pasello, Stefano Indraccolo iD, Valentina Guarneri

Pharmaceutics · 23.07.2026 · 18 (8) · 905

DOI: 10.3390/pharmaceutics18080905 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 23.07.2026. Verfasst von Laura Bonanno und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Oncology and Gastroenterology, University of Padova, 35128 Padova, Italy. Die Arbeit nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The emergence of antibody-drug conjugates (ADCs) targeting trophoblast cell-surface antigen 2 (TROP2) represents a potential paradigm shift in the treatment of EGFR-mutated non-small cell lung cancer (NSCLC), a setting historically characterized by limited therapeutic options following progression on EGFR tyrosine kinase inhibitors (TKIs). This review examines the biological rationale and clinical challenges underpinning the development of anti-TROP2 ADCs in EGFR-mutated NSCLC. From a mechanistic standpoint, TROP2 occupies a unique and dynamic role in EGFR-mutated NSCLC, providing strong biological rationale for clinical development of anti-TROP2 ADCs in this population. Three TROP2-directed ADCs are currently in clinical development in this setting. Available clinical data in previously treated EGFR-mutated patients are critically reviewed here, focusing on efficacy, toxicity profiles, clinical challenges and potential future perspectives.

Schlagwörter

Stichwörter der Autor:innen

ADCEGFROsimertinibTROP-2datopotamab deruxtecandrug-tolerant persistersinterstitial lung diseaseresistancesacituzumab tirumotecan

Autor:innen und Institutionen

  • Department of Surgery, Oncology and Gastroenterology, University of Padova, 35128 Padova, Italy.
  • Medical Oncology 2, Istituto Oncologico Veneto (IOV), IRCCS, 35128 Padova, Italy.
  • Basic and Translational Oncology Unit, Istituto Oncologico Veneto (IOV), IRCCS, 35128 Padova, Italy.

ORCID-Profile: Stefano Indraccolo

Förderung

  • Italian Ministry of Health

Zitieren

APA

Bonanno, L., Ronchi, A., Bao, L. C., Pante, F., Sangiorgi, S., Pasello, G., Indraccolo, S., & Guarneri, V. (2026). Anti-TROP2 Antibody Drug Conjugates in EGFR-Mutant Non-Small Cell Lung Cancer: Biological Rationale and Clinical Challenges. Pharmaceutics, 18(8), 905. https://doi.org/10.3390/pharmaceutics18080905

Vancouver

Bonanno L, Ronchi A, Bao LC, Pante F, Sangiorgi S, Pasello G, et al. Anti-TROP2 Antibody Drug Conjugates in EGFR-Mutant Non-Small Cell Lung Cancer: Biological Rationale and Clinical Challenges. Pharmaceutics. 2026;18(8):905. doi:10.3390/pharmaceutics18080905

BibTeX
@article{Bonanno2026,
  author = {Bonanno, Laura and Ronchi, Alberto and Bao, Loc Carlo and Pante, Francesca and Sangiorgi, Sara and Pasello, Giulia and Indraccolo, Stefano and Guarneri, Valentina},
  title = {Anti-TROP2 Antibody Drug Conjugates in EGFR-Mutant Non-Small Cell Lung Cancer: Biological Rationale and Clinical Challenges},
  journal = {Pharmaceutics},
  year = {2026},
  volume = {18},
  number = {8},
  pages = {905},
  doi = {10.3390/pharmaceutics18080905}
}
Kostenlos starten →